Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016923
Chunk: 171

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 171
---
,000 |   |
| Cost                       |     |           | 2,254,486 |   |     |              | 2,254,486 |   |
| Accumulated amortization   |     |           |           |   |     |              |           |   |
| Trade names and trademarks |     |           |   (12,777 | ) |     |              |   (10,694 | ) |
| Customer relationships     |     |           |   (76,667 | ) |     |              |   (64,167 | ) |
| Accumulated amortization   |     |           |   (89,444 | ) |     |              |   (74,861 | ) |
| Intangible assets, net     |     | $         | 2,165,042 |   |     | $            | 2,179,625 |   |

The Company incurred amortization
of intangible assets of $14,583
for each of the three months ended March 31, 2025 and 2024.

Recent Accounting Pronouncements

The Company continues to monitor new
accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”) and does not believe new accounting
pronouncements issued through the date of this Quarterly Report will have a material impact on the Company’s condensed consolidated
financial statements.

Segment Information

The Company is organized in two
operating segments, Diagnostic Research and Development (“R&D”) and Laboratory Services, whereby its chief operating
decision maker (“CODM”) assesses the performance of and allocates resources. The CODM is the Chief Executive Officer. Diagnostic
R&D includes research and development and clinical development on diagnostic tests. Any revenues assigned to Diagnostic R&D are
proceeds received from observational studies. Laboratory services include all the operations from Village Oaks and PPLS in addition to
sales and marketing costs of CyPathLung from bioAffinity Technologies.

SCHEDULE OF SEGMENT INFORMATION

| Net revenues:                       |     | 2025            
 As of March 31, 
 2025            |            |   |     | 2024 
 2024 |            |   |
|:------------------------------------|:----|:----------------|-----------:|:--|:----|:-----|-----------:|:--|
| Diagnostic R&D                      |     | $               |          — |   |     | $    |      2,885 |   |
| Laboratory services                 |